130 related articles for article (PubMed ID: 27874234)
1. Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.
D'Alessandro PL; Buschmann N; Kaufmann M; Furet P; Baysang F; Brunner R; Marzinzik A; Vorherr T; Stachyra TM; Ottl J; Lizos DE; Cobos-Correa A
Angew Chem Int Ed Engl; 2016 Dec; 55(52):16026-16030. PubMed ID: 27874234
[TBL] [Abstract][Full Text] [Related]
2. A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53
Skalniak L; Twarda-Clapa A; Neochoritis CG; Surmiak E; Machula M; Wisniewska A; Labuzek B; Ali AM; Krzanik S; Dubin G; Groves M; Dömling A; Holak TA
FEBS J; 2019 Apr; 286(7):1360-1374. PubMed ID: 30715803
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
[TBL] [Abstract][Full Text] [Related]
4. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
[TBL] [Abstract][Full Text] [Related]
5. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
6. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
7. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
8. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
Neochoritis CG; Atmaj J; Twarda-Clapa A; Surmiak E; Skalniak L; Köhler LM; Muszak D; Kurpiewska K; Kalinowska-Tłuścik J; Beck B; Holak TA; Dömling A
Eur J Med Chem; 2019 Nov; 182():111588. PubMed ID: 31421630
[TBL] [Abstract][Full Text] [Related]
9. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
[TBL] [Abstract][Full Text] [Related]
11. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
13. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
Weber L
Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
[TBL] [Abstract][Full Text] [Related]
14. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
Aguilar A; Sun W; Liu L; Lu J; McEachern D; Bernard D; Deschamps JR; Wang S
J Med Chem; 2014 Dec; 57(24):10486-98. PubMed ID: 25496041
[TBL] [Abstract][Full Text] [Related]
15. Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction.
Riedinger C; Endicott JA; Kemp SJ; Smyth LA; Watson A; Valeur E; Golding BT; Griffin RJ; Hardcastle IR; Noble ME; McDonnell JM
J Am Chem Soc; 2008 Nov; 130(47):16038-44. PubMed ID: 18959403
[TBL] [Abstract][Full Text] [Related]
16. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
17. A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions.
Lundholt BK; Heydorn A; Bjørn SP; Praestegaard M
Assay Drug Dev Technol; 2006 Dec; 4(6):679-88. PubMed ID: 17199506
[TBL] [Abstract][Full Text] [Related]
18. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of MDM2 and MDMX: a structural perspective.
Riedinger C; McDonnell JM
Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
[TBL] [Abstract][Full Text] [Related]
20. Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors.
Grigoreva TA; Novikova DS; Petukhov AV; Gureev MA; Garabadzhiu AV; Melino G; Barlev NA; Tribulovich VG
Bioorg Med Chem Lett; 2017 Dec; 27(23):5197-5202. PubMed ID: 29089230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]